Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone650-327-3270
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$251.25 million
Profitability
Miscellaneous
Employees166
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions
What is Corcept Therapeutics' stock symbol?
Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."
How were Corcept Therapeutics' earnings last quarter?
Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its earnings results on Thursday, August, 1st. The biotechnology company reported $0.17 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.18 by $0.01. The biotechnology company earned $72.26 million during the quarter, compared to analyst estimates of $70.87 million. Corcept Therapeutics had a return on equity of 27.97% and a net margin of 29.16%. The firm's revenue for the quarter was up 16.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.20 earnings per share. View Corcept Therapeutics' Earnings History.
When is Corcept Therapeutics' next earnings date?
What guidance has Corcept Therapeutics issued on next quarter's earnings?
Corcept Therapeutics issued an update on its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $285-315 million, compared to the consensus revenue estimate of $295.06 million.
What price target have analysts set for CORT?
2 brokerages have issued 12 month target prices for Corcept Therapeutics' shares. Their forecasts range from $11.00 to $14.00. On average, they anticipate Corcept Therapeutics' share price to reach $12.50 in the next twelve months. This suggests that the stock has a possible downside of 0.3%. View Analyst Price Targets for Corcept Therapeutics.
What is the consensus analysts' recommendation for Corcept Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Corcept Therapeutics.
What are Wall Street analysts saying about Corcept Therapeutics stock?
Here are some recent quotes from research analysts about Corcept Therapeutics stock:
- 1. According to Zacks Investment Research, "Corcept is making good progress with its Cushing's syndrome drug, Korlym. The company's efforts to expand Korlym’s label are encouraging and should boost the drug’s commercial potential going forward. The company is making attempts to develop its pipeline with its most advanced candidate relacorilant, currently investigated for Cushing's syndrome. The successful development of its other pipeline candidates (CORT125281 and CORT118335) will further boost the company’s portfolio and lead to increased sales in future. However, Corcept’s share price movement shows that the stock has underperformed the industry year to date. Moreover, Corcept is solely dependent on Korlym for growth. A decline in Korlym sales will hinder the company’s growth prospects in the future quarters." (7/31/2019)
- 2. Cantor Fitzgerald analysts commented, "We have a N rating & a $14 PT for CORT based on our valuation of the Korlym + Rela’ franchise. We believe it’s about Rela’ and our question is when will it successfully complete the P3 in Cushing’s & displace Korlym? This thesis is our primary focus since it announced lower-than-projected Korlym rev for 4Q18 & 2019 guidance that points to limited upside potential (~20% midpoint of $285-315M)." (5/1/2019)
Has Corcept Therapeutics been receiving favorable news coverage?
Media coverage about CORT stock has trended positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Corcept Therapeutics earned a news impact score of 2.5 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the immediate future. View News Stories for Corcept Therapeutics.
Who are some of Corcept Therapeutics' key competitors?
Some companies that are related to Corcept Therapeutics include Amarin (AMRN), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), FibroGen (FGEN), Allakos (ALLK), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), Alkermes (ALKS), Mirati Therapeutics (MRTX), Evotec (EVTCY) and Taro Pharmaceutical Industries (TARO).
What other stocks do shareholders of Corcept Therapeutics own?
Who are Corcept Therapeutics' key executives?
Corcept Therapeutics' management team includes the folowing people:
- Dr. Joseph K. Belanoff, Co-Founder, Pres, CEO & Director (Age 62)
- Mr. Gary Charles Robb, CFO & Sec. (Age 56)
- Mr. Sean Maduck, Sr. VP of Commercial (Age 42)
- Dr. Christopher Shayne James M.D., Director of Investor Relations
- Dr. Hazel Hunt Ph.D., Sr. VP of Research
Who are Corcept Therapeutics' major shareholders?
Corcept Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.83%), Vanguard Group Inc. (9.63%), Ingalls & Snyder LLC (7.42%), Renaissance Technologies LLC (4.92%), Invesco Ltd. (1.61%) and Morgan Stanley (1.38%). Company insiders that own Corcept Therapeutics stock include G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Renee D Gala, Robert S Fishman and Sean Maduck. View Institutional Ownership Trends for Corcept Therapeutics.
Which major investors are selling Corcept Therapeutics stock?
CORT stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Man Group plc, First Trust Advisors LP, Acadian Asset Management LLC, JPMorgan Chase & Co., BlackRock Inc., Parametric Portfolio Associates LLC and Icon Advisers Inc. Co.. Company insiders that have sold Corcept Therapeutics company stock in the last year include G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Robert S Fishman and Sean Maduck. View Insider Buying and Selling for Corcept Therapeutics.
Which major investors are buying Corcept Therapeutics stock?
CORT stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Renaissance Technologies LLC, Nuveen Asset Management LLC, LSV Asset Management, AMI Asset Management Corp, D. E. Shaw & Co. Inc., Ingalls & Snyder LLC and Eaton Vance Management. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.
How do I buy shares of Corcept Therapeutics?
Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corcept Therapeutics' stock price today?
One share of CORT stock can currently be purchased for approximately $12.54.
How big of a company is Corcept Therapeutics?
Corcept Therapeutics has a market capitalization of $1.43 billion and generates $251.25 million in revenue each year. The biotechnology company earns $75.41 million in net income (profit) each year or $0.60 on an earnings per share basis. Corcept Therapeutics employs 166 workers across the globe.View Additional Information About Corcept Therapeutics.
What is Corcept Therapeutics' official website?
How can I contact Corcept Therapeutics?
Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]
MarketBeat Community Rating for Corcept Therapeutics (NASDAQ CORT)
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe CORT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days.
